Every color tells a story, and we want to hear yours — the stories that offer fresh perspectives, inspire hope in the community, connect unexpected ideas, or simply resonate with you on a personal level.
For Rare Disease Day this February, you’ll find a curation of those stories here — The Rare Moments. Patients, families, researchers, and those dedicated to advancing rare disease treatments will be using this space to share their rare stories. From past experiences with lysosomal diseases to significant highlights of the 2025 Rare Disease Day, and even hopes for the future, you will find diverse and valuable insights that matter to our community and expand our understanding of what it means to live with and work with rare diseases.
Be sure to check back regularly throughout the month for the latest posts, and don’t forget to submit your colorful Rare Moments!
Kyle BryantFriedreich’s Ataxia Research Alliance (FARA)
One of the families in our community had an event annually for 10 years that was a 3 day hangout session on a farm for FA families. People camped out, and there were all kinds of activities, such as swimming, fishing, yoga, tie-dying, crafts, fireworks, and all-you-can-eat ice cream. At this event, people with Friedreich’s ataxia (FA) never felt out of place, and we were all able to be together without the awkwardness that can be present around people who might not understand the experience of FA.
My Rare Moment is anytime I get to be with my people.
The Friedreich’s Ataxia Research Alliance (FARA) funds and facilitates research to slow, stop, reverse, and cure Friedreich’s ataxia. FARA is a key resource for both FA families and researchers.
I have seen so many families without hope losing children (young and adults) to rare diseases despite the investment of time/money, and emotions. One of the most fulfilling days for me was when one such family was able to watch their child markedly improve about 8 months after treatment!
I had such a fulfilling experience visiting my members of Congress as part of Rare Disease Week on Capitol Hill. My fellow advocates and I raised our voices to encourage their support of policies that benefit rare disease patients. Hearing everyone’s stories was so inspiring.
We are proud to support and bring awareness to Triple Negative Breast Cancer Day which was yesterday, March 3rd. Individuals in the United States have a 1 in 8 chance of developing breast cancer and TNBC accounts for 10-25% of those breast cancers. Me and many others at Worldwide are excited to take part in the many events occurring throughout March that bring awareness to this disease. Please join us at any of the highlighted events listed below.
In celebration of Rare Disease Day, I am excited to share our most recent draft class from the 2024 Young Investigator Draft! This year we highlighted the significant potential of research in this space when powered by the platform of sports—especially as we surpassed our $1 million in total funding granted. You can watch a recap of the event at the below link!
Jim Geraghty said it best today at the 9th Annual Rare Disease Day Event at the Broad Institute. “It’s a marathon, not a sprint,” when it comes to rare disease research. Always a science-focused and inspiring event at the Broad!
Connecting, Collaborating, Communicating, Challenges: Sharing experiences navigating family conversations in an n-of-1 investigational treatment setting
Monday, March 4, 2024 12:30 pm US ESTFrom an initial email request or conversation at a meeting… to (for some) the possibility of additional assessments… to (for a few) the potential or actual delivery of an n-of-1 treatment to an individual, researchers and clinicians are in contact with patients, families, and caretakers throughout this process. These contact points are crucial for evolving treatment development, but also present challenges on each side. For this webinar, we invite you to join
Happening now through 25 Feb – VCP International Conference!! Check out the abstracts from the many researchers who are participating in this meeting. By bridging the gaps between various disciplines, from oncology to neurodegeneration, the Cure VCP conference will drive innovation and coordination in research, accelerating our progress to find a cure for valosin-containing protein (VCP) associate multisystem proteinopathy (MSP).
The Orphan Drug Act (ODA) of 1983 made the development of desperately needed new treatments for rare disease patient communities a possibility in ways it truly had not been before. Over the 40 years of the ODA, 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases. Additionally, 882 of those designations resulted in at least one FDA approval for use in 392 rare diseases. While having an approved treatment option for 5% of rare disease communities is progress, we’ve seen time and again how partnering with patient communities increases efficiency. Let’s all do more of that!
Worldwide Clinical welcomes you to our site. We collect information about your browsing experience such as cookies, pixels, and web beacons (collectively, “cookies”) to assist with improving your experience with our website. You may ‘Agree’ to accept categories of cookies or ‘Decline’ to reject optional cookies, or otherwise manage your preferences by clicking on the button, ‘Manage Cookie Options‘ below. Worldwide uses Essential Cookies, thus you may not opt of these Cookies as they are deployed to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit our Privacy Policy or Cookie Notice for more information.
One of the families in our community had an event annually for 10 years that was a 3 day hangout session on a farm for FA families. People camped out, and there were all kinds of activities, such as swimming, fishing, yoga, tie-dying, crafts, fireworks, and all-you-can-eat ice cream. At this event, people with Friedreich’s ataxia (FA) never felt out of place, and we were all able to be together without the awkwardness that can be present around people who might not understand the experience of FA.
My Rare Moment is anytime I get to be with my people.
curefa.orgFARA – Friedreich's Ataxia Research Alliance
The Friedreich’s Ataxia Research Alliance (FARA) funds and facilitates research to slow, stop, reverse, and cure Friedreich’s ataxia. FARA is a key resource for both FA families and researchers.
curefa.orgI have seen so many families without hope losing children (young and adults) to rare diseases despite the investment of time/money, and emotions. One of the most fulfilling days for me was when one such family was able to watch their child markedly improve about 8 months after treatment!
Hear from Nathan Chadwick, Senior Director and Therapeutic Strategy Lead for Rare Disease.
youtu.beI had such a fulfilling experience visiting my members of Congress as part of Rare Disease Week on Capitol Hill. My fellow advocates and I raised our voices to encourage their support of policies that benefit rare disease patients. Hearing everyone’s stories was so inspiring.
We are proud to support and bring awareness to Triple Negative Breast Cancer Day which was yesterday, March 3rd. Individuals in the United States have a 1 in 8 chance of developing breast cancer and TNBC accounts for 10-25% of those breast cancers. Me and many others at Worldwide are excited to take part in the many events occurring throughout March that bring awareness to this disease. Please join us at any of the highlighted events listed below.
tnbcfoundation.orgIn celebration of Rare Disease Day, I am excited to share our most recent draft class from the 2024 Young Investigator Draft! This year we highlighted the significant potential of research in this space when powered by the platform of sports—especially as we surpassed our $1 million in total funding granted. You can watch a recap of the event at the below link!
www.youtube.comJim Geraghty said it best today at the 9th Annual Rare Disease Day Event at the Broad Institute. “It’s a marathon, not a sprint,” when it comes to rare disease research. Always a science-focused and inspiring event at the Broad!
Connecting, Collaborating, Communicating, Challenges: Sharing experiences navigating family conversations in an n-of-1 investigational treatment setting. Learn more, below!
www.n1collaborative.orgConnecting, Collaborating, Communicating, Challenges: Sharing experiences navigating family conversations in an n-of-1 investigational treatment setting
Monday, March 4, 2024 12:30 pm US ESTFrom an initial email request or conversation at a meeting… to (for some) the possibility of additional assessments… to (for a few) the potential or actual delivery of an n-of-1 treatment to an individual, researchers and clinicians are in contact with patients, families, and caretakers throughout this process. These contact points are crucial for evolving treatment development, but also present challenges on each side. For this webinar, we invite you to join
www.n1collaborative.orgHappening now through 25 Feb – VCP International Conference!! Check out the abstracts from the many researchers who are participating in this meeting. By bridging the gaps between various disciplines, from oncology to neurodegeneration, the Cure VCP conference will drive innovation and coordination in research, accelerating our progress to find a cure for valosin-containing protein (VCP) associate multisystem proteinopathy (MSP).
www.curevcp.org2024 Poster Session – Cure VCP Disease
www.curevcp.orgThe Orphan Drug Act (ODA) of 1983 made the development of desperately needed new treatments for rare disease patient communities a possibility in ways it truly had not been before. Over the 40 years of the ODA, 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases. Additionally, 882 of those designations resulted in at least one FDA approval for use in 392 rare diseases. While having an approved treatment option for 5% of rare disease communities is progress, we’ve seen time and again how partnering with patient communities increases efficiency. Let’s all do more of that!